Adaptimmune Therapeutics PLC ADR sell nvestor
Start price
30.05.20
/
50%
€9.05
Target price
18.10.20
€4.00
Performance (%)
-37.02%
End price
18.10.20
€5.70
Summary
This prediction ended on 18.10.20 with a price of €5.70. The SELL prediction by nvestor for Adaptimmune Therapeutics PLC ADR performed very well with a performance of -37.02%. nvestor has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Adaptimmune Therapeutics PLC ADR | 10.769% | 10.769% | 43.046% | -70.330% |
iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
According to nvestor what are the pros and cons of Adaptimmune Therapeutics PLC ADR for the foreseeable future?
Pros
Cons
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Bad rating
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Bad culture
Little innovation
Few uniques
Dependend from some customers or products
Below average Marketposition
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation
Low dividend yield expected
negative Cash Flow expected
Little Investments for future growth
Risky balance sheet
Below average Management
Growths slower than the competition
Sustainability is little important
high free float
Higher risks for its business
Significant cyclical dependencies
Little known brand
Business model of the past or high risk
Comments by nvestor for this prediction
In the thread Adaptimmune Therapeutics PLC ADR diskutieren
Sell mit Kursziel 4,0
In the thread Trading Adaptimmune Therapeutics PLC ADR
Sell beendet
Stopped prediction by nvestor for Adaptimmune Therapeutics PLC ADR
Adaptimmune Therapeutics PLC ADR
Start price
Target price
Perf. (%)
€1.07
13.04.24
13.04.24
€1.00
13.04.25
13.04.25
-2.80%
27.04.24
27.04.24
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Bad rating
ROE lower than 10% per year